This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
AVTR Stock Flat Following the Close of Divestiture Deal With Audax
by Zacks Equity Research
Avantor closes its deal with Audax to divest its clinical services business.
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval
by Zacks Equity Research
BSX receives FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing cardiac mapping and ablation workflows for AF treatment.
Cencora Rallies 14.7% Year to Date: What's Driving the Stock?
by Zacks Equity Research
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
Henry Schein Stock Gains From Dental Business Expansion Amid Macro Woe
by Zacks Equity Research
Henry Schein strategically sets up distribution centers worldwide to better serve customers and increase its operating efficiency.
Boston Scientific (BSX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Get a deeper insight into the potential performance of Boston Scientific (BSX) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
by Zacks Equity Research
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
by Zacks Equity Research
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
by Zacks Equity Research
Bruker announces the formation of the new Bruker Spatial Biology division.
Is ResMed Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
RMD's robust mask business and efforts to boost its SaaS business are encouraging.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Boston Scientific (BSX) concluded the recent trading session at $87, signifying a +0.27% move from its prior day's close.
Catalent Stock Flat Following the Sell Agreement With Ardena
by Zacks Equity Research
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
HealthEquity Gains 28.3% YTD: What's Driving the Stock?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Reasons to Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB's strong product demand and continued focus on R&D raise optimism about the stock.
3 Reasons Why Growth Investors Shouldn't Overlook Boston Scientific (BSX)
by Zacks Equity Research
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
by Zacks Equity Research
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
by Zacks Equity Research
BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.
Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?
by Zacks Equity Research
BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.